All Stories

Globus Medical to buy neurostim developer Nevro for $250M

With Globus paying $5.85 for each of Nevro’s outstanding shares, that amounts to a 27% premium over a 90-day weighted average.

Feb 10, 2025 - 17:03
 0
Globus Medical to buy neurostim developer Nevro for $250M
With Globus paying $5.85 for each of Nevro’s outstanding shares, that amounts to a 27% premium over a 90-day weighted average.
Read More

Tags:

Previous Article

Boehringer widens fibrosis drug’s approval path after boosting lung function in ...

Next Article

Applications for new human medicines under evaluation: February 2025

Related Posts

After AI antibodies and peptides, UW’s Baker Lab now tackles computer-generated enzymes

After AI antibodies and peptides, UW’s Baker Lab now ta...

Feb 13, 2025  0

Tandem Diabetes Care insulin-dosing algorithm nets FDA clearance for Type 2 diabetes

Tandem Diabetes Care insulin-dosing algorithm nets FDA ...

Feb 25, 2025  0

Deep Track nominates candidates for Dynavax's board, launching proxy fight to end company's 'empire-building' strategy

Deep Track nominates candidates for Dynavax's board, la...

Feb 19, 2025  0